The "Homeopathic Drug Product Safety, Quality, and Transparency Act" establishes a comprehensive statutory framework for regulating homeopathic drug products under the Federal Food, Drug, and Cosmetic Act. It defines a homeopathic drug product as one containing only homeopathic ingredients, which are listed in recognized pharmacopoeias or prepared using specific homeopathic methods. Crucially, the bill exempts these products from the premarket approval requirements of section 505 of the FFDCA, treating them as a distinct category with appropriate regulatory oversight. The legislation mandates the Secretary of Health and Human Services to issue a final rule within three years, establishing current good manufacturing practices (CGMPs) and labeling requirements tailored to homeopathic products. These rules must be appropriate, consistent with established standards, and avoid requiring analytical methodologies that are not currently available. While exempting finished products from certain active ingredient identity and strength testing, the bill requires testing for contaminants and defects, and for intermediate preparations of high-risk starting materials to ensure they do not exceed a safe level. For labeling, retail homeopathic products must state intended uses for self-limiting conditions and include a disclaimer that the uses have not been evaluated by the FDA. Claims must be supported by competent evidence, including traditional homeopathic principles and real-world evidence, and be preceded by "Traditionally used for." The bill also establishes a Homeopathic Drug Product Advisory Committee to provide recommendations on safety, quality, and labeling standards, and to advise on regulatory approaches, with the Secretary required to consult the committee on significant regulatory actions.